Treatment Options | MS Living Well

AubagioAubagio (teriflunomide) is a once-a-day tablet for the treatment of adults with relapsing forms of multiple sclerosis (MS). The Aubagio 14 mg dose has been shown to reduce relapses by 31.5% in the TEMSO trial and 36% in the TOWER trial. Both trials demonstrated a benefit in reducing the likelihood of disability progression.Learn moreCopaxoneCopaxone (glatiramer acetate) is composed of four amino acids, the building blocks of protein. The daily injection therapy is given under the skin. Copaxone increases immune cells that reduce inflammation. In animal models of MS, these cells traveled to the brain and spinal cord to reduce inflammation.Learn moreInterferonAvonex, Betaseron, Extavia and Rebif are interferon therapies. Interferon is a natural compound that our immune cells make. Interferon treatment can help "quiet down" inflammatory white blood cells and help block these cells from crossing the blood vessel walls into the brain and spinal cord. Fortunately, this anti-inflammatory benefit does not result in increased infections.Learn moreGilenyaGilenya (also known as fingolimod, FTY720) is FDA-approved for the treatment of relapsing forms of MS to reduce the number of relapses and delay the development of disability. Gilenya is taken as a once-day 0.5 mg capsule.Learn moreLemtradaLemtrada (alemtuzumab) is an antibody treatment that is given in the vein over 5 days the first year and 3 days the second year. By reducing certain immune cells from the body for months, Lemtrada has been shown to cut relapses in half compared to interferon treatment.Learn moreNovantroneNovantrone (mitoxantrone) is a powerful medication given in the vein generally every 3 months for up to 2 years. The medication has been shown to reduce relapses by 68%, prevent new MRI activity by 85%, and reduce the risk of disability progression by 62%.Learn moreTecfideraTecfidera ( BG-12, dimethyl fumurate ) is an oral twice daily treatment with anti-oxidant properties for relapsing forms of multiple sclerosis. In clinical trials, Tecfidera dropped relapses by 44-53% compared to placebo.Learn moreTysabriTysabri (natalizumab) is an antibody treatment given in the vein (I.V.) every 4 weeks. Tysabri blocks lymphocytes, a type of white blood cell, from crossing the blood vessel wall to enter the brain or spinal cord.Learn more

Continued here:
Treatment Options | MS Living Well